Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Multiple Sclerosis

  Free Subscription

Articles published in J Neurol

Retrieve available abstracts of 189 articles:
HTML format

Single Articles

    May 2020
  1. TSANTES E, Curti E, Ganazzoli C, Puci F, et al
    The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?
    J Neurol. 2020 May 12. pii: 10.1007/s00415-020-09894.
    PubMed     Abstract available

  2. KOCH MW, Mostert J, Greenfield J, Liu WQ, et al
    Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent.
    J Neurol. 2020 May 9. pii: 10.1007/s00415-020-09895.
    PubMed     Abstract available

  3. COLOMBO C, Confalonieri P, Rovaris M, La Mantia L, et al
    The IN-DEEP project "INtegrating and Deriving Evidence, Experiences, Preferences": a web information model on magnetic resonance imaging for people with multiple sclerosis.
    J Neurol. 2020 May 2. pii: 10.1007/s00415-020-09864.
    PubMed     Abstract available

    April 2020
  4. CHEN MH, Wylie GR, Sandroff BM, Dacosta-Aguayo R, et al
    Neural mechanisms underlying state mental fatigue in multiple sclerosis: a pilot study.
    J Neurol. 2020 Apr 29. pii: 10.1007/s00415-020-09853.
    PubMed     Abstract available

  5. SABIN J, Urtiaga S, Pilo B, Thuissard I, et al
    Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
    J Neurol. 2020 Apr 29. pii: 10.1007/s00415-020-09848.
    PubMed     Abstract available

  6. MATEEN FJ, Vogel AC, Kaplan TB, Hotan GC, et al
    Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09845.
    PubMed     Abstract available

  7. MISICKA E, Sept C, Briggs FBS
    Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.
    J Neurol. 2020 Apr 24. pii: 10.1007/s00415-020-09850.
    PubMed     Abstract available

  8. WILLIS MD, Robertson NP
    Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.
    J Neurol. 2020 Apr 17. pii: 10.1007/s00415-020-09822.

  9. MATTIOLI F, Bellomi F, Stampatori C, Mariotto S, et al
    Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients.
    J Neurol. 2020 Apr 15. pii: 10.1007/s00415-020-09832.
    PubMed     Abstract available

  10. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    J Neurol. 2020 Apr 3. pii: 10.1007/s00415-020-09811.
    PubMed     Abstract available

    March 2020
  11. CAROTENUTO A, Wilson H, Giordano B, Caminiti SP, et al
    Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications.
    J Neurol. 2020 Mar 26. pii: 10.1007/s00415-020-09806.
    PubMed     Abstract available

  12. SHEMA-SHIRATZKY S, Hillel I, Mirelman A, Regev K, et al
    A wearable sensor identifies alterations in community ambulation in multiple sclerosis: contributors to real-world gait quality and physical activity.
    J Neurol. 2020 Mar 12. pii: 10.1007/s00415-020-09759.
    PubMed     Abstract available

  13. MARGONI M, Franciotta S, Poggiali D, Riccardi A, et al
    Cerebellar gray matter lesions are common in pediatric multiple sclerosis at clinical onset.
    J Neurol. 2020 Mar 5. pii: 10.1007/s00415-020-09776.
    PubMed     Abstract available

  14. ZUBER P, Tsagkas C, Papadopoulou A, Gaetano L, et al
    Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results.
    J Neurol. 2020 Mar 2. pii: 10.1007/s00415-020-09768.
    PubMed     Abstract available

    February 2020
  15. HELLWIG K, Geissbuehler Y, Sabido M, Popescu C, et al
    Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.
    J Neurol. 2020 Feb 26. pii: 10.1007/s00415-020-09762.
    PubMed     Abstract available

  16. MAGON S, Tsagkas C, Gaetano L, Patel R, et al
    Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
    J Neurol. 2020 Feb 10. pii: 10.1007/s00415-020-09740.
    PubMed     Abstract available

  17. SCHWEITZER F, Laurent S, Fink GR, Barnett MH, et al
    Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.
    J Neurol. 2020 Feb 8. pii: 10.1007/s00415-019-09690.
    PubMed     Abstract available

  18. KATSARI M, Kasselimis DS, Giogkaraki E, Breza M, et al
    A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?
    J Neurol. 2020 Feb 1. pii: 10.1007/s00415-020-09720.
    PubMed     Abstract available

    January 2020
  19. NESS NH, Schriefer D, Haase R, Ettle B, et al
    Correction to: Differentiating societal costs of disability worsening in multiple sclerosis.
    J Neurol. 2020 Jan 16. pii: 10.1007/s00415-019-09694.
    PubMed     Abstract available

  20. SHAH VV, McNames J, Mancini M, Carlson-Kuhta P, et al
    Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson's disease and matched controls during daily living.
    J Neurol. 2020 Jan 11. pii: 10.1007/s00415-020-09696.
    PubMed     Abstract available

    December 2019
  21. NESS NH, Schriefer D, Haase R, Ettle B, et al
    Differentiating societal costs of disability worsening in multiple sclerosis.
    J Neurol. 2019 Dec 17. pii: 10.1007/s00415-019-09676.
    PubMed     Abstract available

  22. HEDSTROM AK, Olsson T, Kockum I, Hillert J, et al
    Low sun exposure increases multiple sclerosis risk both directly and indirectly.
    J Neurol. 2019 Dec 17. pii: 10.1007/s00415-019-09677.
    PubMed     Abstract available

  23. DAVDA N, Tallantyre E, Robertson NP
    Early MRI predictors of prognosis in multiple sclerosis.
    J Neurol. 2019;266:3171-3173.

    November 2019
  24. LIN WS, Wang HP, Chen HM, Lin JW, et al
    Epidemiology of pediatric multiple sclerosis, neuromyelitis optica, and optic neuritis in Taiwan.
    J Neurol. 2019 Nov 28. pii: 10.1007/s00415-019-09647.
    PubMed     Abstract available

  25. TAVAZZI E, Bergsland N, Kuhle J, Jakimovski D, et al
    A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    J Neurol. 2019 Nov 25. pii: 10.1007/s00415-019-09643.
    PubMed     Abstract available

  26. SIERRA MORALES F, Koralnik IJ, Gautam S, Samaan S, et al
    Correction to: Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    J Neurol. 2019 Nov 23. pii: 10.1007/s00415-019-09626.
    PubMed     Abstract available

  27. PROSPERINI L, Cortese A, Lucchini M, Boffa L, et al
    Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.
    J Neurol. 2019 Nov 13. pii: 10.1007/s00415-019-09625.
    PubMed     Abstract available

  28. LECLER A, Bouzad C, Deschamps R, Maizeroi F, et al
    Optimizing 3D FLAIR to detect MS lesions: pushing past factory settings for precise results.
    J Neurol. 2019;266:2786-2795.
    PubMed     Abstract available

    October 2019
  29. MIRAFZAL S, Goujon A, Deschamps R, Zuber K, et al
    3D PSIR MRI at 3 Tesla improves detection of spinal cord lesions in multiple sclerosis.
    J Neurol. 2019 Oct 26. pii: 10.1007/s00415-019-09591.
    PubMed     Abstract available

  30. FUJIMORI J, Fujihara K, Ogawa R, Baba T, et al
    Patterns of regional brain volume loss in multiple sclerosis: a cluster analysis.
    J Neurol. 2019 Oct 25. pii: 10.1007/s00415-019-09595.
    PubMed     Abstract available

  31. SINNECKER T, Ruberte E, Schadelin S, Canova V, et al
    New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
    J Neurol. 2019 Oct 14. pii: 10.1007/s00415-019-09565.
    PubMed     Abstract available

  32. KAMM CP, Barin L, Gobbi C, Pot C, et al
    Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
    J Neurol. 2019 Oct 8. pii: 10.1007/s00415-019-09563.
    PubMed     Abstract available

  33. ROMEO MAL, Garassino MC, Moiola L, Galli G, et al
    Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    J Neurol. 2019 Oct 4. pii: 10.1007/s00415-019-09562.

  34. MORALES FS, Koralnik IJ, Gautam S, Samaan S, et al
    Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    J Neurol. 2019 Oct 3. pii: 10.1007/s00415-019-09557.
    PubMed     Abstract available

    September 2019
  35. MARGONI M, Rinaldi F, Riccardi A, Franciotta S, et al
    No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab.
    J Neurol. 2019 Sep 27. pii: 10.1007/s00415-019-09554.
    PubMed     Abstract available

  36. PAOLICELLI D, Lucisano G, Manni A, Avolio C, et al
    Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
    J Neurol. 2019 Sep 18. pii: 10.1007/s00415-019-09531.
    PubMed     Abstract available

  37. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2019 Sep 17. pii: 10.1007/s00415-019-09535.
    PubMed     Abstract available

  38. GRANELLA F, Tsantes E, Graziuso S, Bazzurri V, et al
    Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey.
    J Neurol. 2019 Sep 7. pii: 10.1007/s00415-019-09526.
    PubMed     Abstract available

  39. SHEMA-SHIRATZKY S, Gazit E, Sun R, Regev K, et al
    Deterioration of specific aspects of gait during the instrumented 6-min walk test among people with multiple sclerosis.
    J Neurol. 2019 Sep 6. pii: 10.1007/s00415-019-09500.
    PubMed     Abstract available

  40. CHOUTEAU R, Combes B, Bannier E, Snoussi H, et al
    Joint assessment of brain and spinal cord motor tract damage in patients with early RRMS: predominant impact of spinal cord lesions on motor function.
    J Neurol. 2019;266:2294-2303.
    PubMed     Abstract available

    August 2019
  41. STORELLI L, Rocca MA, Pantano P, Pagani E, et al
    MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis.
    J Neurol. 2019 Aug 17. pii: 10.1007/s00415-019-09509.
    PubMed     Abstract available

    July 2019
  42. INOJOSA H, Proschmann U, Akgun K, Ziemssen T, et al
    A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.
    J Neurol. 2019 Jul 30. pii: 10.1007/s00415-019-09489.
    PubMed     Abstract available

  43. RASTAS C, Sirignano D, Barner A, Bruno-Murtha LA, et al
    Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis.
    J Neurol. 2019 Jul 26. pii: 10.1007/s00415-019-09483.

  44. MO XB, Lei SF, Qian QY, Guo YF, et al
    Integrative analysis revealed potential causal genetic and epigenetic factors for multiple sclerosis.
    J Neurol. 2019 Jul 18. pii: 10.1007/s00415-019-09476.
    PubMed     Abstract available

  45. MICHAEL G, Christian E, Fritz L, Jorg K, et al
    Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2019 Jul 16. pii: 10.1007/s00415-019-09464.
    PubMed     Abstract available

  46. RAIMO S, Trojano L, Gaita M, Spitaleri D, et al
    High openness and high extroversion are linked with better time-based prospective memory in multiple sclerosis.
    J Neurol. 2019 Jul 16. pii: 10.1007/s00415-019-09460.
    PubMed     Abstract available

  47. AYRIGNAC X, Rigau V, Lhermitte B, Vincent T, et al
    Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.
    J Neurol. 2019;266:1743-1755.
    PubMed     Abstract available

    June 2019
  48. BERENGUER-RUIZ L, Gimenez-Martinez J, Palazon-Bru A, Sempere AP, et al
    Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
    J Neurol. 2019 Jun 29. pii: 10.1007/s00415-019-09450.
    PubMed     Abstract available

  49. FRAU J, Sacca F, Signori A, Baroncini D, et al
    Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    J Neurol. 2019 Jun 17. pii: 10.1007/s00415-019-09424.
    PubMed     Abstract available

  50. SPARACO M, Lavorgna L, Bonavita S
    Psychiatric disorders in multiple sclerosis.
    J Neurol. 2019 Jun 13. pii: 10.1007/s00415-019-09426.
    PubMed     Abstract available

  51. CUNNIFFE N, Coles A
    Promoting remyelination in multiple sclerosis.
    J Neurol. 2019 Jun 12. pii: 10.1007/s00415-019-09421.
    PubMed     Abstract available

  52. KEARNS PKA, Paton M, O'Neill M, Waters C, et al
    Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register.
    J Neurol. 2019 Jun 11. pii: 10.1007/s00415-019-09413.
    PubMed     Abstract available

    May 2019
  53. SODERHOLM J, Yilmaz A, Svenningsson A, Busch K, et al
    Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study.
    J Neurol. 2019 May 31. pii: 10.1007/s00415-019-09397.
    PubMed     Abstract available

  54. LI H, Hu F, Zhang Y, Li K, et al
    Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09395.
    PubMed     Abstract available

  55. GAETANI L, Salvadori N, Lisetti V, Eusebi P, et al
    Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09398.
    PubMed     Abstract available

  56. DUDEK MIR, Thies K, Kammenhuber S, Bosel J, et al
    HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab.
    J Neurol. 2019 May 21. pii: 10.1007/s00415-019-09391.

  57. LANGENBRUCH L, Kramer J, Guler S, Moddel G, et al
    Seizures and epilepsy in multiple sclerosis: epidemiology and prognosis in a large tertiary referral center.
    J Neurol. 2019 May 8. pii: 10.1007/s00415-019-09332.
    PubMed     Abstract available

  58. PANTAVOU KG, Bagos PG
    Season of birth and multiple sclerosis: a systematic review and multivariate meta-analysis.
    J Neurol. 2019 May 4. pii: 10.1007/s00415-019-09346.
    PubMed     Abstract available

    April 2019
  59. PUST GEA, Pottgen J, Randerath J, Lau S, et al
    In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients.
    J Neurol. 2019 Apr 19. pii: 10.1007/s00415-019-09311.
    PubMed     Abstract available

    March 2019
  60. GAO J, Jones J, Damato EM, Coles A, et al
    Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    J Neurol. 2019 Mar 20. pii: 10.1007/s00415-019-09288.

  61. FRAU J, Coghe G, Lorefice L, Fenu G, et al
    Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
    J Neurol. 2019 Mar 12. pii: 10.1007/s00415-019-09272.
    PubMed     Abstract available

  62. NYE CJS, Wagner A, Kousin-Ezewu O, Jones JL, et al
    A case of anaphylaxis to alemtuzumab.
    J Neurol. 2019;266:780-781.

    February 2019
  63. TURNER B, Cree BAC, Kappos L, Montalban X, et al
    Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
    J Neurol. 2019 Feb 28. pii: 10.1007/s00415-019-09248.
    PubMed     Abstract available

  64. RICHTER S, Wagner B, Celius EG
    Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
    J Neurol. 2019 Feb 25. pii: 10.1007/s00415-019-09257.

  65. PERSSON R, Lee S, Yood MU, Wagner M, et al
    Multi-database study of multiple sclerosis: identification, validation and description of MS patients in two countries.
    J Neurol. 2019 Feb 18. pii: 10.1007/s00415-019-09238.
    PubMed     Abstract available

  66. JAKIMOVSKI D, Weinstock-Guttman B, Gandhi S, Guan Y, et al
    Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.
    J Neurol. 2019 Feb 13. pii: 10.1007/s00415-019-09208.
    PubMed     Abstract available

  67. LEBRUN-FRENAY C, Moulignier A, Pierrot-Deseilligny C, Benrabah R, et al
    Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
    J Neurol. 2019 Feb 7. pii: 10.1007/s00415-019-09211.
    PubMed     Abstract available

  68. GAMRAOUI S, Mathey G, Debouverie M, Malaplate C, et al
    High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.
    J Neurol. 2019 Feb 1. pii: 10.1007/s00415-019-09212.
    PubMed     Abstract available

  69. D'AMICO E, Zanghi A, Sciandra M, Borriello G, et al
    Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.
    J Neurol. 2019;266:411-416.
    PubMed     Abstract available

  70. CHALMER TA, Kalincik T, Laursen B, Sorensen PS, et al
    Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
    J Neurol. 2019;266:306-315.
    PubMed     Abstract available

    January 2019
  71. ALCALA C, Gascon F, Perez-Miralles F, Dominguez JA, et al
    Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
    J Neurol. 2019 Jan 19. pii: 10.1007/s00415-019-09195.
    PubMed     Abstract available

  72. LAVORGNA L, Esposito S, Lanzillo R, Sparaco M, et al
    Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.
    J Neurol. 2019 Jan 16. pii: 10.1007/s00415-019-09193.
    PubMed     Abstract available

  73. HARTUNG HP, Graf J, Kremer D
    Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study.
    J Neurol. 2019 Jan 4. pii: 10.1007/s00415-018-09169.
    PubMed     Abstract available

  74. PFEUFFER S, Schmidt R, Straeten FA, Pul R, et al
    Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
    J Neurol. 2019;266:165-173.
    PubMed     Abstract available

    December 2018
  75. SONG J, Westerlind H, McKay KA, Almqvist C, et al
    Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study.
    J Neurol. 2018 Dec 21. pii: 10.1007/s00415-018-9163.
    PubMed     Abstract available

  76. JOHNEN A, Burkner PC, Landmeyer NC, Ambrosius B, et al
    Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).
    J Neurol. 2018 Dec 4. pii: 10.1007/s00415-018-9142.
    PubMed     Abstract available

  77. BRAUNE S, Grimm S, van Hovell P, Freudensprung U, et al
    Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    J Neurol. 2018;265:2980-2992.
    PubMed     Abstract available

    November 2018
  78. MEGNA R, Alfano B, Lanzillo R, Costabile T, et al
    Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment.
    J Neurol. 2018 Nov 29. pii: 10.1007/s00415-018-9139.
    PubMed     Abstract available

  79. KILJAN S, Meijer KA, Steenwijk MD, Pouwels PJW, et al
    Structural network topology relates to tissue properties in multiple sclerosis.
    J Neurol. 2018 Nov 22. pii: 10.1007/s00415-018-9130.
    PubMed     Abstract available

  80. HARDING KE, Robertson NP
    New rare genetic variants in multiple sclerosis.
    J Neurol. 2018 Nov 20. pii: 10.1007/s00415-018-9128.

  81. RIEDERER I, Muhlau M, Hoshi MM, Zimmer C, et al
    Detecting optic nerve lesions in clinically isolated syndrome and multiple sclerosis: double-inversion recovery magnetic resonance imaging in comparison with visually evoked potentials.
    J Neurol. 2018 Nov 16. pii: 10.1007/s00415-018-9114.
    PubMed     Abstract available

  82. SAEZ MS, Rojas JI, Lorenzon MV, Sanchez F, et al
    Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires.
    J Neurol. 2018 Nov 1. pii: 10.1007/s00415-018-9106.
    PubMed     Abstract available

  83. STAMPANONI BASSI M, Iezzi E, Landi D, Monteleone F, et al
    Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course.
    J Neurol. 2018;265:2540-2547.
    PubMed     Abstract available

    October 2018
  84. ELLRICHMANN G, Bolz J, Peschke M, Duscha A, et al
    Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders.
    J Neurol. 2018 Oct 30. pii: 10.1007/s00415-018-9092.
    PubMed     Abstract available

  85. MCLAUGHLIN L, Clarke L, Khalilidehkordi E, Butzkueven H, et al
    Vitamin D for the treatment of multiple sclerosis: a meta-analysis.
    J Neurol. 2018 Oct 3. pii: 10.1007/s00415-018-9074.
    PubMed     Abstract available

  86. TOMMASIN S, De Giglio L, Ruggieri S, Petsas N, et al
    Relation between functional connectivity and disability in multiple sclerosis: a non-linear model.
    J Neurol. 2018 Oct 1. pii: 10.1007/s00415-018-9075.
    PubMed     Abstract available

    September 2018
  87. PROSPERINI L, Annovazzi P, Boffa L, Buscarinu MC, et al
    No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    J Neurol. 2018 Sep 26. pii: 10.1007/s00415-018-9070.
    PubMed     Abstract available

  88. TUDOR KI, Eames S, Haslam C, Chataway J, et al
    Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis.
    J Neurol. 2018 Sep 19. pii: 10.1007/s00415-018-9064.
    PubMed     Abstract available

  89. FAKIH R, Matiello M, Chitnis T, Stankiewicz JM, et al
    Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.
    J Neurol. 2018 Sep 10. pii: 10.1007/s00415-018-9050.
    PubMed     Abstract available

  90. GAETANI L, Prosperini L, Mancini A, Eusebi P, et al
    2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.
    J Neurol. 2018 Sep 8. pii: 10.1007/s00415-018-9048.
    PubMed     Abstract available

  91. CAMBRON M, Reynders T, Debruyne J, Reyngoudt H, et al
    Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI, (1)H and (31)P MRS, and clinical and cognitive testing.
    J Neurol. 2018 Sep 5. pii: 10.1007/s00415-018-9039.
    PubMed     Abstract available

    August 2018
  92. FILSER M, Schreiber H, Pottgen J, Ullrich S, et al
    The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study.
    J Neurol. 2018 Aug 31. pii: 10.1007/s00415-018-9034.
    PubMed     Abstract available

  93. BABER U, Bouley A, Egnor E, Sloane JA, et al
    Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
    J Neurol. 2018 Aug 14. pii: 10.1007/s00415-018-8996.
    PubMed     Abstract available

  94. RUMPF JJ, Dietrich S, Stoppe M, Fricke C, et al
    Compromised tDCS-induced facilitation of motor consolidation in patients with multiple sclerosis.
    J Neurol. 2018 Aug 6. pii: 10.1007/s00415-018-8993.
    PubMed     Abstract available

  95. SEITZ CB, Droby A, Zaubitzer L, Kramer J, et al
    Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.
    J Neurol. 2018 Aug 2. pii: 10.1007/s00415-018-8988.
    PubMed     Abstract available

  96. MALLUCCI G, Annovazzi P, Miante S, Torri-Clerici V, et al
    Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
    J Neurol. 2018;265:1850-1859.
    PubMed     Abstract available

    July 2018
  97. FROHLICH K, Winder K, Linker RA, Huhn K, et al
    Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.
    J Neurol. 2018 Jul 31. pii: 10.1007/s00415-018-8989.
    PubMed     Abstract available

  98. COCOZZA S, Pontillo G, Russo C, Russo CV, et al
    Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?
    J Neurol. 2018 Jul 28. pii: 10.1007/s00415-018-8985.
    PubMed     Abstract available

  99. BALLOY G, Pelletier J, Suchet L, Lebrun C, et al
    Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
    J Neurol. 2018 Jul 27. pii: 10.1007/s00415-018-8984.
    PubMed     Abstract available

  100. BARONE S, Caligiuri ME, Valentino P, Cherubini A, et al
    Multimodal assessment of normal-appearing corpus callosum is a useful marker of disability in relapsing-remitting multiple sclerosis: an MRI cluster analysis study.
    J Neurol. 2018 Jul 26. pii: 10.1007/s00415-018-8980.
    PubMed     Abstract available

  101. GALGANI S, Prosperini L, Haggiag S, Tortorella C, et al
    Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.
    J Neurol. 2018 Jul 17. pii: 10.1007/s00415-018-8976.

  102. ALADRO Y, Lopez-Alvarez L, Sanchez-Reyes JM, Hernandez-Tamames JA, et al
    Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis.
    J Neurol. 2018 Jul 11. pii: 10.1007/s00415-018-8965.
    PubMed     Abstract available

  103. KALLWEIT U, Bassetti CLA, Oberholzer M, Fronczek R, et al
    Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis : Six new cases and a literature review.
    J Neurol. 2018 Jul 4. pii: 10.1007/s00415-018-8949.
    PubMed     Abstract available

    June 2018
  104. BAJRAMI A, Pitteri M, Castellaro M, Pizzini F, et al
    The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
    J Neurol. 2018 Jun 25. pii: 10.1007/s00415-018-8952.
    PubMed     Abstract available

  105. MOTTE J, Kneiphof J, Strassburger-Krogias K, Klasing A, et al
    Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.
    J Neurol. 2018 Jun 15. pii: 10.1007/s00415-018-8931.
    PubMed     Abstract available

    May 2018
  106. MARSHALL I, Thrippleton MJ, Bastin ME, Mollison D, et al
    Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.
    J Neurol. 2018 May 30. pii: 10.1007/s00415-018-8903.
    PubMed     Abstract available

  107. YAMAGUCHI H, Sakai K, Goto Y, Yamada M, et al
    Autoimmune hepatitis induced by a single injection of interferon-beta 1a in a patient with multiple sclerosis.
    J Neurol. 2018 May 29. pii: 10.1007/s00415-018-8912.

  108. SANTANGELO G, Bisecco A, Trojano L, Sacco R, et al
    Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures.
    J Neurol. 2018 May 26. pii: 10.1007/s00415-018-8905.
    PubMed     Abstract available

  109. ALCALA C, Gascon F, Perez-Miralles F, Gil-Perotin S, et al
    Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
    J Neurol. 2018 May 21. pii: 10.1007/s00415-018-8899.
    PubMed     Abstract available

  110. KOCSIK AS, Klein DE, Liedke M, Kaunzner UW, et al
    Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
    J Neurol. 2018;265:1226-1229.
    PubMed     Abstract available

  111. OPFER R, Ostwaldt AC, Walker-Egger C, Manogaran P, et al
    Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.
    J Neurol. 2018;265:1158-1165.
    PubMed     Abstract available

    April 2018
  112. RASUL T, Frederiksen JL
    Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis.
    J Neurol. 2018 Apr 26. pii: 10.1007/s00415-018-8869.
    PubMed     Abstract available

  113. HUHN K, Bayas A, Doerck S, Frank B, et al
    Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    J Neurol. 2018 Apr 25. pii: 10.1007/s00415-018-8871.
    PubMed     Abstract available

  114. TAVAZZI E, Bergsland N, Cattaneo D, Gervasoni E, et al
    Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.
    J Neurol. 2018 Apr 7. pii: 10.1007/s00415-018-8859.
    PubMed     Abstract available

    March 2018
  115. COGHE G, Corona F, Marongiu E, Fenu G, et al
    Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.
    J Neurol. 2018 Mar 24. pii: 10.1007/s00415-018-8836.
    PubMed     Abstract available

  116. NAKKEN O, Lindstrom JC, Holmoy T
    Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway.
    J Neurol. 2018 Mar 21. pii: 10.1007/s00415-018-8832.
    PubMed     Abstract available

  117. CERONIE B, Jacobs BM, Baker D, Dubuisson N, et al
    Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    J Neurol. 2018 Mar 17. pii: 10.1007/s00415-018-8830.
    PubMed     Abstract available

  118. LANZILLO R, Prosperini L, Gasperini C, Moccia M, et al
    A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
    J Neurol. 2018 Mar 16. pii: 10.1007/s00415-018-8831.
    PubMed     Abstract available

  119. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
    J Neurol. 2018 Mar 12. pii: 10.1007/s00415-018-8813.
    PubMed     Abstract available

  120. DEVONSHIRE V, Phillips R, Wass H, Da Roza G, et al
    Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    J Neurol. 2018 Mar 10. pii: 10.1007/s00415-018-8822.
    PubMed     Abstract available

  121. HOTTENROTT T, Schorb E, Fritsch K, Dersch R, et al
    The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
    J Neurol. 2018 Mar 6. pii: 10.1007/s00415-018-8779.
    PubMed     Abstract available

  122. LOREFICE L, Fenu G, Pitzalis R, Scalas G, et al
    Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.
    J Neurol. 2018 Mar 5. pii: 10.1007/s00415-018-8811.
    PubMed     Abstract available

    February 2018
  123. BROICHER SD, Filli L, Geisseler O, Germann N, et al
    Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8796.
    PubMed     Abstract available

  124. VAN DER VUURST DE VRIES RM, Mescheriakova JY, Runia TF, Siepman TAM, et al
    Smoking at time of CIS increases the risk of clinically definite multiple sclerosis.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8780.
    PubMed     Abstract available

  125. BELL JS, Spencer JI, Yates RL, DeLuca GC, et al
    The cortical blood-brain barrier in multiple sclerosis: a gateway to progression?
    J Neurol. 2018 Feb 13. pii: 10.1007/s00415-017-8727.

  126. ESPOSITO F, Ferre L, Clarelli F, Rocca MA, et al
    Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    J Neurol. 2018 Feb 12. pii: 10.1007/s00415-018-8791.
    PubMed     Abstract available

  127. ARNETH B
    Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections.
    J Neurol. 2018 Feb 8. pii: 10.1007/s00415-018-8783.
    PubMed     Abstract available

  128. SOLARO C, Cella M, Signori A, Martinelli V, et al
    Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.
    J Neurol. 2018 Feb 5. pii: 10.1007/s00415-018-8758.
    PubMed     Abstract available

  129. KALRON A, Allali G, Achiron A
    Cerebellum and cognition in multiple sclerosis: the fall status matters.
    J Neurol. 2018 Feb 2. pii: 10.1007/s00415-018-8774.
    PubMed     Abstract available

  130. WINDER K, Linker RA, Seifert F, Deutsch M, et al
    Insular multiple sclerosis lesions are associated with erectile dysfunction.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8763.
    PubMed     Abstract available

  131. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8764.
    PubMed     Abstract available

  132. FRAU J, Carai M, Coghe G, Fenu G, et al
    Long-term follow-up more than 10 years after HSCT: a monocentric experience.
    J Neurol. 2018;265:410-416.
    PubMed     Abstract available

  133. HONGELL K, Silva DG, Ritter S, Meier DP, et al
    Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.
    J Neurol. 2018;265:348-355.
    PubMed     Abstract available

    January 2018
  134. FIENE M, Rufener KS, Kuehne M, Matzke M, et al
    Electrophysiological and behavioral effects of frontal transcranial direct current stimulation on cognitive fatigue in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8754.
    PubMed     Abstract available

  135. LEAVITT VM, Tosto G, Riley CS
    Cognitive phenotypes in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8747.
    PubMed     Abstract available

  136. DI GREGORIO M, Gaetani L, Eusebi P, Floridi P, et al
    Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    J Neurol. 2018 Jan 11. pii: 10.1007/s00415-017-8726.
    PubMed     Abstract available

  137. ALENDA R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, et al
    Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.
    J Neurol. 2018;265:24-31.
    PubMed     Abstract available

    December 2017
  138. FRAU J, Villar LM, Sardu C, Secci MA, et al
    Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8716.
    PubMed     Abstract available

  139. BRENTON JN, Schreiner T, Karoscik K, Richter M, et al
    Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis.
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8715.
    PubMed     Abstract available

  140. SHRIBMAN S, Hasan H, Hadavi S, Giovannoni G, et al
    The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis.
    J Neurol. 2017 Dec 4. pii: 10.1007/s00415-017-8690.
    PubMed     Abstract available

    November 2017
  141. THALER C, Faizy TD, Sedlacik J, Bester M, et al
    The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8683.
    PubMed     Abstract available

  142. CONRADSSON D, Ytterberg C, von Koch L, Johansson S, et al
    Changes in disability in people with multiple sclerosis: a 10-year prospective study.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8676.
    PubMed     Abstract available

  143. ELIASDOTTIR O, Hildeman A, Longfils M, Nerman O, et al
    A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8665.
    PubMed     Abstract available

  144. RUPRECHT K, Wildemann B, Jarius S
    Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.
    J Neurol. 2017 Nov 2. doi: 10.1007/s00415-017-8656.
    PubMed     Abstract available

    October 2017
  145. COMI G, Patti F, Rocca MA, Mattioli FC, et al
    Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8642.
    PubMed     Abstract available

  146. PARDO G, Jones DE
    Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8633.
    PubMed     Abstract available

    September 2017
  147. LOREFICE L, Coghe G, Fenu G, Porta M, et al
    'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.
    J Neurol. 2017 Sep 11. doi: 10.1007/s00415-017-8612.
    PubMed     Abstract available

  148. PARDO G, Jones DE
    The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Sep 6. doi: 10.1007/s00415-017-8594.
    PubMed     Abstract available

    August 2017
  149. LATTANZI S, Danni M, Taffi R, Cerqua R, et al
    Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    J Neurol. 2017 Aug 22. doi: 10.1007/s00415-017-8595.
    PubMed     Abstract available

  150. HRASTELJ J, Robertson N
    Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8584.

    July 2017
  151. EICHINGER P, Wiestler H, Zhang H, Biberacher V, et al
    A novel imaging technique for better detecting new lesions in multiple sclerosis.
    J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8576.
    PubMed     Abstract available

    June 2017
  152. HAGSTROM IT, Schneider R, Bellenberg B, Salmen A, et al
    Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.
    J Neurol. 2017 Jun 9. doi: 10.1007/s00415-017-8537.
    PubMed     Abstract available

    May 2017
  153. BRITZE J, Pihl-Jensen G, Frederiksen JL
    Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.
    J Neurol. 2017 May 31. doi: 10.1007/s00415-017-8531.
    PubMed     Abstract available

  154. DIBLEY L, Coggrave M, McClurg D, Woodward S, et al
    "It's just horrible": a qualitative study of patients' and carers' experiences of bowel dysfunction in multiple sclerosis.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8527.
    PubMed     Abstract available

  155. FOULON S, Maura G, Dalichampt M, Alla F, et al
    Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8513.
    PubMed     Abstract available

  156. LATTANZI S, Cagnetti C, Danni M, Provinciali L, et al
    Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    J Neurol. 2017 May 10. doi: 10.1007/s00415-017-8505.
    PubMed     Abstract available

    April 2017
  157. HARDING K, Tilling K, MacIver C, Willis M, et al
    Seasonal variation in multiple sclerosis relapse.
    J Neurol. 2017 Apr 19. doi: 10.1007/s00415-017-8485.
    PubMed     Abstract available

  158. SARTORI A, Abdoli M, Freedman MS
    Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    J Neurol. 2017 Apr 17. doi: 10.1007/s00415-017-8487.
    PubMed     Abstract available

  159. HAINLINE C, Rizzo JR, Hudson TE, Dai W, et al
    Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.
    J Neurol. 2017 Apr 7. doi: 10.1007/s00415-017-8484.
    PubMed     Abstract available

    March 2017
  160. PREZIOSA P, Martinelli V, Ferre L, Guaschino C, et al
    Moyamoya disease mimicking the first attack of multiple sclerosis.
    J Neurol. 2017 Mar 17. doi: 10.1007/s00415-017-8458.

  161. MCLAUCHLAN D, Robertson NP
    B cell treatments for multiple sclerosis.
    J Neurol. 2017 Mar 4. doi: 10.1007/s00415-017-8442.

  162. KHAN F, Amatya B, Galea MP, Gonzenbach R, et al
    Neurorehabilitation: applied neuroplasticity.
    J Neurol. 2017;264:603-615.
    PubMed     Abstract available

    February 2017
  163. DULAU C, Deloire M, Diaz H, Saubusse A, et al
    Social cognition according to cognitive impairment in different clinical phenotypes of multiple sclerosis.
    J Neurol. 2017 Feb 20. doi: 10.1007/s00415-017-8417.
    PubMed     Abstract available

  164. NIJ BIJVANK JA, Balk LJ, Tan HS, Uitdehaag BM, et al
    A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer.
    J Neurol. 2017 Feb 13. doi: 10.1007/s00415-017-8412.

  165. MALONEY E, Molloy A, Al Hussona M, O'Donnell L, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    J Neurol. 2017;264:401-403.

    December 2016
  166. HYNCICOVA E, Vyhnalek M, Kalina A, Martinkovic L, et al
    Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis.
    J Neurol. 2016 Dec 27. doi: 10.1007/s00415-016-8368.
    PubMed     Abstract available

  167. JARIUS S, Eichhorn P, Franciotta D, Petereit HF, et al
    The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature.
    J Neurol. 2016 Dec 22. doi: 10.1007/s00415-016-8360.
    PubMed     Abstract available

  168. BRECKWOLDT MO, Gradl J, Hahnel S, Hielscher T, et al
    Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.
    J Neurol. 2016.
    PubMed     Abstract available

  169. HUSS AM, Halbgebauer S, Ockl P, Trebst C, et al
    Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
    J Neurol. 2016;263:2499-2504.
    PubMed     Abstract available

    November 2016
  170. BLOCK VJ, Lizee A, Crabtree-Hartman E, Bevan CJ, et al
    Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.
    J Neurol. 2016.
    PubMed     Abstract available

  171. BLASCO MR, Ramos A, Malo CG, Garcia-Merino A, et al
    Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.
    J Neurol. 2016.

  172. SCHWARTZBACH CJ, Grove RA, Brown R, Tompson D, et al
    Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
    J Neurol. 2016.
    PubMed     Abstract available

  173. PROSPERINI L, Sacca F, Cordioli C, Cortese A, et al
    Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Abstract available

  174. KOSMIDOU M, Katsanos AH, Katsanos KH, Kyritsis AP, et al
    Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis.
    J Neurol. 2016.
    PubMed     Abstract available

  175. HAVLA J, Kumpfel T, Schinner R, Spadaro M, et al
    Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    J Neurol. 2016.
    PubMed     Abstract available

    October 2016
  176. DRESSLER D, Bhidayasiri R, Bohlega S, Chahidi A, et al
    Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
    J Neurol. 2016.
    PubMed     Abstract available

  177. VAN GEEST Q, Westerik B, van der Werf YD, Geurts JJ, et al
    The role of sleep on cognition and functional connectivity in patients with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Abstract available

  178. THORMANN A, Magyari M, Koch-Henriksen N, Laursen B, et al
    Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.
    J Neurol. 2016.
    PubMed     Abstract available

  179. ABSINTA M, Reich DS, Filippi M
    Spring cleaning: time to rethink imaging research lines in MS?
    J Neurol. 2016;263:1893-902.
    PubMed     Abstract available

    September 2016
  180. OWEN PICKRELL W, Robertson NP
    Stem cell treatment for multiple sclerosis.
    J Neurol. 2016.

  181. MAILLART E, Papeix C, Mellerio C, Bertrand A, et al
    Extensive and severe CNS demyelination associated with golimumab therapy.
    J Neurol. 2016;263:1869-71.

    August 2016
  182. ZURAWSKI J, Flinn A, Sklover L, Sloane JA, et al
    Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
    J Neurol. 2016;263:1511-7.
    PubMed     Abstract available

    July 2016
  183. BALK LJ, Cruz-Herranz A, Albrecht P, Arnow S, et al
    Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
    J Neurol. 2016;263:1323-31.
    PubMed     Abstract available

  184. HAVRDOVA E, Belova A, Goloborodko A, Tisserant A, et al
    Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
    J Neurol. 2016;263:1287-95.
    PubMed     Abstract available

    May 2016
  185. AMANN M, Pezold S, Naegelin Y, Fundana K, et al
    Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
    J Neurol. 2016.
    PubMed     Abstract available

    March 2016
  186. HUSSAIN R, O'Leary S, Pacheco FM, Zacharias TE, et al
    Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
    J Neurol. 2016;263:606-10.
    PubMed     Abstract available

  187. FILIPPI M, Barker RA, Strupp M
    The neurology community mourns the passing of Dr. John F. Kurtzke.
    J Neurol. 2016;263:421.

    February 2016
  188. JEFFERY DR, Di Cantogno EV, Ritter S, Meier DP, et al
    The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.
    J Neurol. 2016;263:299-305.
    PubMed     Abstract available

    January 2016
  189. JURYNCZYK M, Weinshenker B, Akman-Demir G, Asgari N, et al
    Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.
    J Neurol. 2016;263:140-9.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.